Amarin - The Science Of Lipid Therapy (Seite 84)
eröffnet am 03.01.14 20:10:32 von
neuester Beitrag 04.04.24 15:47:54 von
neuester Beitrag 04.04.24 15:47:54 von
Beiträge: 1.840
ID: 1.190.027
ID: 1.190.027
Aufrufe heute: 0
Gesamt: 156.370
Gesamt: 156.370
Aktive User: 0
ISIN: US0231112063 · WKN: A0NBNG · Symbol: AMRN
0,8749
USD
+1,72 %
+0,0148 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
24.04.24 · globenewswire  |
22.04.24 · globenewswire |
15.04.24 · globenewswire |
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 08.04.24 · globenewswire |
06.04.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,9000 | +305,04 | |
| 1,3254 | +82,86 | |
| 0,6500 | +25,75 | |
| 6,0000 | +25,00 | |
| 56,69 | +20,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,1200 | -12,17 | |
| 8,5000 | -15,00 | |
| 0,7300 | -18,59 | |
| 92,06 | -19,84 | |
| 2,7280 | -29,14 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 63.675.997 von bluespin am 14.05.20 11:21:40INVESTOR RELATIONS
VASCEPA® (ICOSAPENT ETHYL) SHOWS SIGNIFICANT REDUCTION IN CORONARY REVASCULARIZATION, INCLUDING CORONARY STENTING AND CARDIAC BYPASS SURGERY, IN PRESPECIFIED AND POST HOC ANALYSES OF LANDMARK REDUCE-IT® STUDY
https://investor.amarincorp.com/news-releases/news-release-d…
VASCEPA® (ICOSAPENT ETHYL) SHOWS SIGNIFICANT REDUCTION IN CORONARY REVASCULARIZATION, INCLUDING CORONARY STENTING AND CARDIAC BYPASS SURGERY, IN PRESPECIFIED AND POST HOC ANALYSES OF LANDMARK REDUCE-IT® STUDY https://investor.amarincorp.com/news-releases/news-release-d…
Yes we hope, aber sicher ist Nichts!
@magetfeldfredy, ich habe eben nochmal für 2000 € Amarin zu 6,65 nachgekauft. Ich denke ja auch, dass die Aktie MINDESTENS wieder auf 10 € steigt. 825 Stk. habe ich jetzt. Dann lohnt es sich schon etwas :-)
Antwort auf Beitrag Nr.: 63.681.193 von PC-DIDI am 14.05.20 16:13:31heute fallen alle Biotec-Aktien. Sind zuletzt ja auch gut gelaufen.
Drecksshorts und korrupte Richter sind der Grund, aber das Blatt wird sich wenden:
Patent attorney finds Amarin appeal brief effective, says H.C. Wainwright
With Amarin having filed its opening appeal brief with the U.S. Court of Appeals for the Federal Circuit, H.C. Wainwright analyst Andrew Fein consulted with a patent attorney on initial perspectives. The patent attorney concluded that Amarin has done a thorough job presenting its case and effectively presented its opening shot in the best light possible, Fein tells investors in a research note. The attorney further believed the brief explained the Vascepa technology and the basis of the invention thoroughly, why it was needed and the approach the inventor took to solve the problem of lowering triglycerides in patients with severe hyperlipidemia without raisi ng LDLs, adds the analyst. Fein points out that Amarin essentially has two main lines of argument: that the court erred in finding a prima facie case of obviousness because it did not apply the correct analytical framework and erred in its approach to secondary considerations. Fein's consulted attorney found Amarin's second line of argument compelling, both on the merits and on the clarity and force of argument. That said, the company only needs to be right on one, Fein adds. He keeps a Buy rating on Amarin with a $51 price target
Patent attorney finds Amarin appeal brief effective, says H.C. Wainwright
With Amarin having filed its opening appeal brief with the U.S. Court of Appeals for the Federal Circuit, H.C. Wainwright analyst Andrew Fein consulted with a patent attorney on initial perspectives. The patent attorney concluded that Amarin has done a thorough job presenting its case and effectively presented its opening shot in the best light possible, Fein tells investors in a research note. The attorney further believed the brief explained the Vascepa technology and the basis of the invention thoroughly, why it was needed and the approach the inventor took to solve the problem of lowering triglycerides in patients with severe hyperlipidemia without raisi ng LDLs, adds the analyst. Fein points out that Amarin essentially has two main lines of argument: that the court erred in finding a prima facie case of obviousness because it did not apply the correct analytical framework and erred in its approach to secondary considerations. Fein's consulted attorney found Amarin's second line of argument compelling, both on the merits and on the clarity and force of argument. That said, the company only needs to be right on one, Fein adds. He keeps a Buy rating on Amarin with a $51 price target
Trading Spotlight
Was nutzen uns die schönsten Meldungen, wenn die Aktie wieder so abstürzt wie heute! Gibt es da irgendeinen logischen Grund für?
Antwort auf Beitrag Nr.: 63.675.997 von bluespin am 14.05.20 11:21:40Reduction of Revascularizations in Patients with Hypertriglyceridemia With Icosapent Ethyl: Insights From REDUCE-IT REVASC 👍
Deepak.L.Bhatt auf Twitter :
Zitat von bluespin: https://scai.confex.com/scai/2020/meetingapp.cgi/Paper/11665
Deepak.L.Bhatt auf Twitter :
Antwort auf Beitrag Nr.: 63.675.706 von Magnetfeldfredy am 14.05.20 11:06:52
Reduction of Revascularizations in Patients with Hypertriglyceridemia With Icosapent Ethyl: Insights From REDUCE-IT REVASC
https://scai.confex.com/scai/2020/meetingapp.cgi/Paper/11665 
Antwort auf Beitrag Nr.: 63.664.270 von tippse am 13.05.20 16:18:48
https://drive.google.com/file/d/1sAKuDK5aB6EW896vYPS8qocP5gR…
masterpiece
Zitat von tippse: Weißt Du, wo kann man Singers "masterpiece" einsehen kann?
https://drive.google.com/file/d/1sAKuDK5aB6EW896vYPS8qocP5gR…
Durchsuchen
Amarin - The Science Of Lipid Therapy
